NanoViricides starts Phase II DRC trial of oral NV-387 for Ebola

The company said it began enrolling and dosing patients in Democratic Republic of Congo study of NV-387 oral gummies for Bundibugyo ebolavirus. It said the initial dose run-in is intended to set a tolerable dosing approach before later randomized efficacy testing.